GeNeuro temporarily suspends MS trial, will focus on COVID-19 efforts
Category: #health  By Mateen Dalal  Date: 2020-03-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

GeNeuro temporarily suspends MS trial, will focus on COVID-19 efforts

  • The pharmaceutical firm will prioritize resources towards COVID-19 pandemic
  • Phase 2 trial in MS patients will commence once the hospitals have enough research capacity

Switzerland based biopharmaceutical firm- GeNeuro has recently announced temporary halt of its Phase 2 clinical trial of temelimab used in the treatment of multiple sclerosis, at the Karolinska Institutet’s Academic Specialist Center, Sweden, owing to the need to cater to the healthcare resource requirements to fight Coronavirus pandemic and to reduce the exposure to risk among MS patients.

According to Jesús Martin-Garcia, CEO, GeNeuro, the postponement is a necessary decision undertaken by the company to help meet the medical requirements of coronavirus and prioritize the treatment of the infected patients. The decision also aims at safeguarding the health of patients diagnosed with multiple sclerosis, he further stated.

Reportedly, the Phase 2 trial will be initiated once the hospitals have enough capacities to carry out clinical research and ensure that the patients will not be exposed to any type of risk.

For the record, the one-year clinical trial will register patients who do not witness any relapses and will document the safety and tolerability of temelimab after injecting with higher dosage, along with efficacy based on the latest biomarkers linked with disease progression.

Founded in the year 2006, GeNeuro is a clinical stage pharmaceutical headquartered in Zurich that aims at understanding and restricting the factors that drive the development of neurodegenerative and autoimmune diseases, including multiple sclerosis The company has its R&D center in Lyon, France and comprises of 23 employees and the right to over 17 patents safeguarding its technology.

Many other clinical trials and research work have been impacted owing to the COVID-19 threat globally. These include postponing of a registration study for Parkinson’s treatment, as well as separate trials of COPD, geographic atrophy, cancer treatment, among others, undertaken by several companies and in different stages of research.

Source Credits: http://www.geneuro.com/data/news/GeNeuro-PR-TemelimabCOVID19-EN.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Netsmart introduces unique mobile screening solution for COVID-19
Netsmart introduces unique mobile screening solution for COVID-19
By Mateen Dalal

In the face of the ongoing pandemic spread worldwide, that has disrupted businesses and turned normal lives upside down, companies have been striving to bring about innovative solutions that can ensure people to remain adequately and correctly inform...

First suspected cases of MIS-C under examination in South Korea
First suspected cases of MIS-C under examination in South Korea
By Mateen Dalal

Health authorities in South Korea have lately announced the ongoing medical examination of two children cited as suspected cases of a life-threatening syndrome associated with coronavirus. The two children are apparently the first suspected cases of ...

SpaceX raises $346 million a day before its debut astronaut mission
SpaceX raises $346 million a day before its debut astronaut mission
By Mateen Dalal

SpaceX recently raised about $346.2 million in the latest funding round just a day before it launches its latest manned spacecraft to the International Space Station. This launch of the first crewed mission from NASA's Space Center in Kennedy, Fl...